Improved Detection and Evaluation of Depression in Patients with Chronic Kidney Disease: Validity and Reliability of Screening (PHQ-2) and Diagnostic (BDI-FS-Fr) Tests of Depression in Chronic Kidney Disease

Alsaleh, Muaweah; Videloup, Ludivine; Lobbedez, Thierry; Lebreuilly, Joëlle; Morello, Rémy; Lecouf, Angélique Thuillier

doi:10.1159/000497352

Cited by 9 publications

(8 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Although the screening instruments used in this study are well validated and commonly used in ESKD population, the lower rate of anxiety seen may be due to failure of these instruments to capture the effects of the pandemic. [6,18] These scales were not designed to evaluate symptoms due to such an ongoing and uncertain life event and only ask about symptoms over the last 2 weeks. Another possible explanation may be that when this survey was conducted in May 2020, the number of COVID-19 cases were low at both sites, although they were rising in NM and falling in Western PA. [19,20] However, despite the low cases, significant worry and stress were reported similarly among participants at both sites.…”

Section: Discussionmentioning

confidence: 99%

“…We adapted the CoRonavIruS Health Impact Survey , and asked whether the symptoms had changed since the pandemic started. [6][7][8][9] These instruments were chosen based on their psychometric properties in ESKD patients and brevity (to minimize participant burden). Lastly, we added questions on participant's concerns for in-center HD, their adherence to HD, preferences for home dialysis and their ability to do telemedicine sessions from home.…”

Section: Survey Instrumentmentioning

confidence: 99%

See 1 more Smart Citation

Psychosocial Impact of COVID-19 Pandemic on Patients with End-Stage Kidney Disease on Hemodialysis

et al. 2020

View full text Add to dashboard Cite

Background: The Coronavirus Disease 2019 (COVID-19) may have a negative effect on the mental and social health of patients with end-stage kidney disease on chronic in-center hemodialysis (HD), who have a high burden of psychological symptoms at baseline and unavoidable treatment-related COVID exposures. The goal of our study was to assess the impact of the COVID-19 pandemic on the psychosocial health of patients on chronic in-center HD. Methods: Participants enrolled in the ongoing Technology Assisted Collaborative Care (TĀCcare) trial in Western Pennsylvania and New Mexico were approached for participation in a phone survey in May 2020. Data on the pandemic's effect on participants' physical and mental health, symptoms (such as anxiety, mood, loneliness, sleep and stress), food and housing security was collected. Results: Surveys were completed by 49 participants (mean age 56 years, 53% males, 18% African American, 20% American Indian, 22% Hispanic). Almost 80% of participants reported being moderately-to-extremely worried about the pandemic's effect on their mental/emotional health and interpersonal relationships. More than 85% of the participants were worried about obtaining their dialysis treatments due to infection risk from close contact in the dialysis facility or during transportation. Despite this, 82% of participants reported being not at all/slightly interested in trying home dialysis as an alternative option. Overall, 27% of the participants had clinical levels of depressive symptoms but only 12% had anxiety meeting clinical criteria. About 33% of participants reported poor sleep quality over the last month. Perceived stress was high in about 30% of participants and 85% felt overwhelmed by difficulties with COVID-19, although 41% felt that things were fairly/very often going their way. Conclusions: Our study provides preliminary insights into the psychosocial distress caused by the COVID-19 pandemic among a diverse cohort of patients receiving chronic hemodialysis who are participating in an ongoing clinical trial.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Survey Instrumentmentioning

confidence: 99%

Psychosocial Impact of COVID-19 Pandemic on Patients with End-Stage Kidney Disease on Hemodialysis

et al. 2020

View full text Add to dashboard Cite

show abstract

“…Other studies carried out on depression in chronic pathologies also recommend the BDI as a good self-assessment tool for screening and evaluation in clinical practice of depression, its intensity, and its evolution in patients with chronic kidney disease [ 40 ]. As depression not only affects patients with MS or other chronic diseases but also their family environment, the BDI proved to be a valid and reliable instrument to measure depression in the family caregivers of children with chronic diseases [ 41 ].…”

Section: Discussionmentioning

confidence: 99%

“…Taking into account our findings and the bibliographic review, it is necessary for patients with MS to be aware of the importance of depression on their quality of life and to offer them a multidisciplinary team to establish good management of this pathology. In addition, biomarkers have been studied in some research with MS subjects, but all of them refer to the need for a larger sample for better consistency to thus complete the aspects of depressive studies and their possible causes in MS [ 11 , 40 ].…”

Section: Discussionmentioning

confidence: 99%

Impact of Multiple Sclerosis and Its Association with Depression: An Analytical Case-Control Investigation

et al. 2022

View full text Add to dashboard Cite

Multiple sclerosis (MS) is a neurological, chronic, inflammatory, and progressive disease with musculoskeletal problems and neurodegenerative disorders that causes worsening of the health status of patients. The aim of this study was to determine the level of depression in MS patients compared to a population of healthy subjects. The established sample size was 116 subjects matched with the same age, sex, and body mass index. The subjects were recruited from different multiple sclerosis associations and neurology clinics in different public health areas (case group n = 58) and healthy subjects from the same locality (control group n = 58). The scores and categories of the Beck Depression Inventory (BDI) in its Spanish version were collected. There was a clear statistically significant difference (p < 0.05) in the BDI scores between both groups. As a result, we found that the subjects with MS presented worse results with BDI = 9.52 ± 7.70 points compared to the healthy subjects with a BDI score = 5.03 ± 5.14. Within the BDI categories, there were statistically significant differences (p < 0.001), which were greater for the MS group. Depression is a dangerous factor for MS patients, being a trigger for a poorer quality of life.

show abstract

“…Biomarkers of CKD 6,7,[12][13][14][15][16][17][18][19][20][24][25][26] recommend that primary care physicians discuss those patients at risk for progression of CKD with their local nephrologist. It is highly encouraged to refer a patient during and after stage 3 CKD.…”

Section: Tablementioning

confidence: 99%

Chronic Kidney Disease: Detection and Evaluation

Pettitt

Brumbaugh

Gartman

et al. 2020

OFP

View full text Add to dashboard Cite

Chronic kidney disease (CKD) is a prevalent disease that continues to affect more than one-tenth of the American population. Early detection is essential to slow the natural progression of CKD. This can be accomplished by urine and blood screening tests, which are analyzed for creatinine, urine albumin, and urine protein. Screening is often indicated for individuals with known comorbidities such as cardiovascular disease, mineral and bone disorders, and diabetes. Asymptomatic patients with early renal disease can make detection problematic, requiring clinicians to recognize risk factors that may warrant further testing. When symptoms do appear, the renal manifestations are often broad, including changes in kidney size, electrolyte abnormalities, and proteinuria. Changes in biomarkers may be evaluated in the early stages of CKD before significant kidney damage. The current, most accurate determination of renal function is the estimated glomerular filtration rate (GFR), which must be less than 60 mL/min to prompt further testing for CKD. Novel biomarkers may allow for earlier diagnosis of CKD as they can be detected at lower levels than standard biomarkers. Biomarkers such as homocysteine, cystatin C, and kidney injury molecule-1 are predicted to become more prevalent in a clinical setting. The current gold standard for diagnosis of CKD is a renal biopsy, but MRI is a less invasive alternative. Proper staging of CKD allows for appropriate evaluation and treatment of the patient. The early stages of CKD should be treated to limit complications and to prolong the life and health of patients.

show abstract

Improved Detection and Evaluation of Depression in Patients with Chronic Kidney Disease: Validity and Reliability of Screening (PHQ-2) and Diagnostic (BDI-FS-Fr) Tests of Depression in Chronic Kidney Disease

Cited by 9 publications

References 31 publications

Psychosocial Impact of COVID-19 Pandemic on Patients with End-Stage Kidney Disease on Hemodialysis

Psychosocial Impact of COVID-19 Pandemic on Patients with End-Stage Kidney Disease on Hemodialysis

Impact of Multiple Sclerosis and Its Association with Depression: An Analytical Case-Control Investigation

Chronic Kidney Disease: Detection and Evaluation

Contact Info

Product

Resources

About